JanOne announced today that it has been granted a U.S. patent for its innovative formulation, known as Jan123, which is designed to treat pain. This news has caused the company’s shares to soar, reaching a high of 85 cents per share during today’s trading session.
Jan123 is specifically being developed to address the complex regional pain syndrome (CRPS), a condition characterized by prolonged pain and inflammation in an injured limb. CRPS is notoriously difficult to treat, with no known cure approved by the U.S. Food and Drug Administration for this particular condition.
However, multiple studies and case reports have shown promising results with low-dose naltrexone, which provides symptom relief to patients suffering from CRPS. JanOne’s patent highlights that their formulation not only alleviates pain but also has the potential to target the underlying disease itself, offering significant benefits to patients.
With this latest patent approval, JanOne further solidifies its position as a leader in developing innovative solutions for pain management. Their dedication to finding effective treatments for CRPS is commendable and brings hope to those living with this debilitating condition.
